In Korea, addressing drug audit findings involves reviewing the audit report, identifying non-compliance issues, implementing corrective actions, and documenting changes. Regulatory authorities must be notified, and follow-up audits ensure compliance. Continuous monitoring and staff training are essential to maintain adherence to regulations... Read More
Drug registration typically requires local clinical studies to ensure safety and efficacy for the Korean population. However, foreign clinical trial data may be accepted if they meet Korean regulatory standards and are supplemented with bridging studies to address any ethnic differences. Read More
Drug companies in China should ensure compliance with NMPA regulations, maintain accurate and up-to-date documentation, conduct regular internal audits, train staff on regulatory requirements, implement robust quality control systems, and stay informed about regulatory changes to be prepared for NMPA audits. Read More
Penalties for non-compliance with GMP standards in China include fines, suspension or revocation of manufacturing licenses, product recalls, and potential criminal charges. Companies may also face reputational damage and restrictions on market access. Regulatory authorities enforce these penalties to ensure public safety... Read More
The drug registration process in China typically takes 12 to 18 months. This includes preclinical studies, dossier review, and regulatory review by the National Medical Products Administration (NMPA). Timelines can vary based on the drug’s complexity, whether a China local clinical study... Read More
In China, both local and foreign clinical trials are accepted for drug approval. However, foreign clinical trial data must meet Chinese regulatory standards. Often, supplementary local trials are required to ensure the drug’s safety and efficacy in the Chinese population, aligning with... Read More
Yes, changes can be made to an already submitted China DMF. These changes must be reported to the National Medical Products Administration (NMPA) through a formal amendment process, including detailed documentation of the modifications. The NMPA will review and approve the changes... Read More
Yes, drug audits are essential in Korea for drug registration. They ensure compliance with regulatory standards, verify the accuracy of submitted data, and maintain public safety. Audits help identify potential issues in manufacturing, quality control, and documentation, thereby ensuring that only safe... Read More
The drug registration process in Korea typically takes around 12 to 24 months. This includes the data review, and regulatory approval by the Ministry of Food and Drug Safety (MFDS). The timeline can vary depending on the drug’s complexity whether a local... Read More
Yes, registering drugs in China requires meeting Good Manufacturing Practice (GMP) standards. The National Medical Products Administration (NMPA) mandates compliance with GMP guidelines to ensure drug safety, quality, and efficacy. Manufacturers must undergo rigorous inspections and obtain GMP certification as part of... Read More